GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » 5-Year RORE %

Sonoma Pharmaceuticals (STU:O8Z3) 5-Year RORE % : -20.55% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Sonoma Pharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2023 was -20.55%.

The industry rank for Sonoma Pharmaceuticals's 5-Year RORE % or its related term are showing as below:

STU:O8Z3's 5-Year RORE % is ranked worse than
74.45% of 912 companies
in the Drug Manufacturers industry
Industry Median: 3.1 vs STU:O8Z3: -20.55

Sonoma Pharmaceuticals 5-Year RORE % Historical Data

The historical data trend for Sonoma Pharmaceuticals's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals 5-Year RORE % Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.97 -53.25 106.23 -54.57 -54.86

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.87 -54.86 -37.00 -25.12 -20.55

Competitive Comparison of Sonoma Pharmaceuticals's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's 5-Year RORE % falls into.



Sonoma Pharmaceuticals 5-Year RORE % Calculation

Sonoma Pharmaceuticals's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.875--2.757 )/( -9.157-0 )
=1.882/-9.157
=-20.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Sonoma Pharmaceuticals  (STU:O8Z3) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Sonoma Pharmaceuticals 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines